TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: (3)He ADC in the apical lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recovery rate from otitis media with effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA damage protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Folate concentration in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Homocysteine concentration in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of women reporting pain relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Systemic mean LIF concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of warm water or tea bag compresses for sore nipples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p55 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood Volume (BV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Flow (BF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perfusion Score (PS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean level of pain 4 h postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean opioid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymph node assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in voiding symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LUTDSS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provocative dose causing a 20% fall in FEV1 (PD20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fewer hand movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Smoother movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Less time taken
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in nighttime fears
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in sleep disruptions
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Implant failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bone loss around implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: time to successful discontinuation of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SEBT reach improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FADi and FADI-Sport scores improvements
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: HRSD improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BDI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMSE improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Average discharge time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Negative societal attitudes towards pregnant women with disabilities
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge of partner violence resources
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-efficacy to enact harm reduction behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reproductive coercion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: nominal change in normalized total atheroma volume (TAV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: death or HF hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: left ventricular ejection fraction (LVEF) ≤35%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Medical costs
Endpoint domain: Resource use
Primary endpoint: Need for educator to recommend escalation of care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Self-perceived confidence following intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Medical Emergency Team call prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proprioception scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional knee movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in MARS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in DAI score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of UI episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical attachment levels (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VPGL (Vascular Permeability Glycoprotein Level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion rates for OHIP 14 and OIDP
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Humoral immune response to RZV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Indexed left ventricular volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Indexed right ventricular volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Indexed left ventricular stroke volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Indexed right ventricular stroke volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: comfort talking to patients about recurring symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incisor retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrusion of the root apex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: applicability of EMB regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: side effects of SM regimen
Endpoint domain: Adverse events/effects
Primary endpoint: cost comparison between SM and EMB
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in serum C-reactive protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in erythrocyte sedimentation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean average BCVA gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to interpret 2D images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of motor disturbance
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of limbs numbness
Endpoint domain: Adverse events/effects
Primary endpoint: Surgical Site Infection (SSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrinogen level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum creatine kinase (CK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: atrogin-1 mRNA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: atrogin-1 protein concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: poly-Ub proteins concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of treatments required before recovery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Development of clinically significant corneal scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean K value of the apex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with the intervention
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Use of evidence in practice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of plasma HIV‐1 RNA to undetectable levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI response in the dorsolateral prefrontal cortex to methylphenidate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intent to change doctors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: tooth loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tooth tender to percussion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean learning test coefficients
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean trail making coefficients
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clinical remission at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of days alive and out of hospital at 1 year
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients with increased oral temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worsening post-infusion symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular event occurrence
Endpoint domain: Mortality/survival
Primary endpoint: Participant satisfaction with care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: plaque removing capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gingival abrasions
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of LVH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean gradient of aortic valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area of the aortic valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Life expectancy ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CRBSI rate
Endpoint domain: Mortality/survival
Primary endpoint: Control of dental stain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumour volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical remission evaluated by normalized IGF-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stinging scores
Endpoint domain: Adverse events/effects
Primary endpoint: Use of community-based mental health treatment programs
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Increase in moderate-to-vigorous physical activity (MVPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in relative V˙O2peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin picking severity at post-measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stridor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of math problems attempted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall clinical functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates for RTF
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Narcotic use reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Wound exudate volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gastrointestinal adverse events (mucositis and diarrhoea)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of swallowing, gagging, movement and laryngospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median compliance with guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-density lipoprotein cholesterol decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to second disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD3 and CD4 positive cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma levels of IgA and IgM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: intestinal mucosal barrier index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in signs of dry eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Schirmer test values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in break-up time test values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arterial ammonia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: evoked responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number connection test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Urinary N-telopeptide excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Calcium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Naltrexone plasma concentrations measurable for at least 31 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean apparent elimination half-lives for naltrexone and 6beta-naltrexol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No serious adverse events occurred
Endpoint domain: Adverse events/effects
Primary endpoint: Na:K ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean percentage change in LS and TH BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Mean total image quality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of images acceptable for clinical use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total episode-of-care costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: complete or near-complete remission of skin lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: FPG values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of insertion attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gastric insufflation
Endpoint domain: Adverse events/effects
Primary endpoint: risk of choline-related organ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rectal fistulas
Endpoint domain: Adverse events/effects
Primary endpoint: Collagen volume fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial hydroxyproline concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: success of restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral hygiene improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for future restorative treatments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percent atheroma volume (PAV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: frequency of combined atherosclerosis regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Total hands-off chest time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion with correct hand position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in basophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: progression of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amplitude or implicit times of N1, P1, or N2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to axillary lymph node recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Rate of Perceived Exertion (RPE) effectiveness in guiding exercise intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cord S100ß levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of infants with cord S100ß value above the 75th percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cord neuroketal levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean blood loss per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adherence to fluticasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physicians' recommendation for maintenance fluticasone
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: serum [Na+] increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in biPTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in iPTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportions of parents actively using guidelines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: rate of any stroke or death
Endpoint domain: Mortality/survival
Primary endpoint: Clinically significant change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative mood alleviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of responders according to OMERACT-OARSI response criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAS-cog/11-K score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: DAD-K score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BEHAVE-AD-K score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MBF ratio at ulcer margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nicotine dependence predicted abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma serotonin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: adrenocorticotropic hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adrenocorticotropic hormone (ACTH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: decreased reported stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in proinflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum trace element status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: enzymatic activities of Cp and SOD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Root mean square of differences between adjacent normal‐to‐normal intervals (RMSSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of Rofecoxib compared to Diclofenac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of AZM suppository
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRs score distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes